Enanta Pharmaceuticals, Inc. (ENTA) Given Average Rating of “Buy” by Brokerages
Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have been assigned a consensus rating of “Buy” from the seven analysts that are covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $38.00.
A number of analysts have recently commented on ENTA shares. Zacks Investment Research raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, June 27th. Robert W. Baird lifted their price target on Enanta Pharmaceuticals from $27.00 to $36.00 and gave the company a “neutral” rating in a research note on Tuesday, August 8th. BidaskClub raised Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, August 11th. ValuEngine raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, J P Morgan Chase & Co reissued an “overweight” rating and set a $38.00 price target (up from $32.00) on shares of Enanta Pharmaceuticals in a research note on Wednesday, August 9th.
Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) traded down 2.60% during mid-day trading on Friday, reaching $42.71. The company’s stock had a trading volume of 140,087 shares. Enanta Pharmaceuticals has a 12 month low of $22.17 and a 12 month high of $45.74. The company has a 50-day moving average of $41.09 and a 200-day moving average of $34.67. The firm’s market cap is $815.33 million.
Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.44) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.49) by $0.05. Enanta Pharmaceuticals had a negative return on equity of 7.74% and a negative net margin of 51.85%. The firm had revenue of $7.51 million for the quarter, compared to analyst estimates of $8.08 million. During the same period last year, the firm posted ($0.06) earnings per share. The business’s revenue for the quarter was down 46.3% on a year-over-year basis. On average, analysts predict that Enanta Pharmaceuticals will post $1.14 earnings per share for the current year.
Several institutional investors and hedge funds have recently modified their holdings of ENTA. Stonepine Capital Management LLC raised its position in shares of Enanta Pharmaceuticals by 165.9% during the second quarter. Stonepine Capital Management LLC now owns 492,265 shares of the biotechnology company’s stock worth $17,712,000 after acquiring an additional 307,166 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Enanta Pharmaceuticals by 129.7% during the first quarter. Dimensional Fund Advisors LP now owns 413,089 shares of the biotechnology company’s stock worth $12,723,000 after acquiring an additional 233,265 shares during the last quarter. State Street Corp raised its position in shares of Enanta Pharmaceuticals by 31.8% during the first quarter. State Street Corp now owns 748,824 shares of the biotechnology company’s stock worth $23,063,000 after acquiring an additional 180,586 shares during the last quarter. ING Groep NV bought a new position in shares of Enanta Pharmaceuticals during the second quarter worth about $3,274,000. Finally, Point72 Asset Management L.P. bought a new position in shares of Enanta Pharmaceuticals during the first quarter worth about $1,731,000. Institutional investors own 66.07% of the company’s stock.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.